The Birmingham-based compliance provider has raised capital to support product innovation and future acquisitions.
"This investment is a momentous milestone for the business. Since we founded in 2022, we’ve been high growth and laser-focused on building the best compliance consultancy in the UK, assembling a team dedicated to excellent personal service. We’re delighted to be working alongside BGF, developing a partnership that will allow us to access the funding, experience and expertise we need to take advantage of the opportunities that lie ahead."
The digital health provider has raised a £45m Series B extension and growth capital package led by Big Pi Ventures and HSBC Innovation Banking.
"Our latest funding is a testament to both our commercial performance and belief in our long-term vision for providing personalised, preventative health at scale. With the fresh conviction of Big Pi Ventures, Endeavor Catalyst and HSBC Innovation Banking – as well as the continued backing of White Star Capital and our long-term investors – we are now perfectly positioned to expand our reach, deepen our clinical capabilities, and accelerate innovation to help our patients live happier, healthier, longer lives."
The former Scotland footballer has backed the medical app and will also assume an ambassadorial role with the company.
"I've had a good relationship with Jonny for a long time, working with him right through youth and senior levels with the Scotland team and then into management and coaching. The demand on players has never been greater and the margins of winning are finer than they have ever been, which only makes products like ScribePro more important. Technology like this can make things better for everyone involved in sport. From my experience as a player when I had some injury problems myself I know the process of sharing or even accessing fitness and injury data could be clunky, to say the least. And I'm looking forward to helping develop the platform further, supporting the decisions managers make with players and working with clinicians on recovery programmes and availability."
The financing round was led by Ahren Innovation Capital and will support the expansion of the company's in-house target discovery programme.
"OutSee’s Nomaly technology is a truly next-generation genomic analysis tool with potential to transform drug discovery using powerful data-driven insights. It allows us to interrogate smaller datasets, and even data that has already been analysed, to uncover unique target insights that until now would have remained undetected."
